Compound ID | 3408
RBX7455
Synonym(s): RBX-7455 | RBX 7455
| Agent Type: | Indirect acting; |
| Spectrum of activity: | Gram-positive |
| Target Pathogen: | Active against Clostridioides difficile; indicated for recurrent C. difficile infection |
| Description: | Live biotherapeutic product (microbiota) prepared from human stool; a microbiome modulating agent |
| Institute where first reported: | Ferring Pharmaceuticals (Rebiotix) |
| Year first mentioned: | 2020 |
| Highest development stage: | Phase 1 (NCT02981316) |
| Development status: | Active |
| External links: | |
| Citation: | https://academic.oup.com/cid/article/73/7/e1613/5910606 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.